| Literature DB >> 28317282 |
Trude E Robsahm1, Ragnhild S Falk2, Trond Heir3, Leiv Sandvik2, Linda Vos1, Jan Erikssen3, Steinar Tretli1,4.
Abstract
Based on self-reported physical activity, there is epidemiologic evidence for a beneficial relation between physical activity and colon cancer in men, but findings for other cancers are inconclusive. Measured cardiorespiratory fitness (CRF) can provide knowledge about the cancer-preventive value of physical activity. We aimed to assess relationships between CRF and risk of site-specific cancers. A cohort of 1997 healthy Norwegian men, aged 40-59 years at inclusion in 1972-1975, was followed for cancer throughout 2012 using data from the Cancer Registry of Norway. CRF was measured by a maximal exercise bicycle test at inclusion. Relationships between CRF and site-specific cancers were estimated using Cox regression, adjusted for age, body mass index, and smoking. During follow-up, 898 cancer cases were diagnosed in 758 men. When comparing men in CRF tertile 1 with men in tertiles 2 and 3, respectively, we found decreased risk of proximal colon cancer in tertile 2 (HR: 0.30, 95% CI: 0.13-0.73) and decreased risk of cancers of lung (0.39 95% CI: 0.22-0.66), pancreas (0.32 95% CI: 0.10-1.00), and bladder (HR: 0.40 95% CI: 0.21-0.74) in tertile 3. Furthermore, a significant trend for lower risk by increasing CRF tertile was found for cancers of proximal colon, lung, and bladder (P-value for trend <0.05). For other cancer sites, no significant association was found. Our results indicate that high midlife CRF may have cancer-preventive value.Entities:
Keywords: Cancer risk; cardiorespiratory fitness; measurement; prevention
Mesh:
Year: 2017 PMID: 28317282 PMCID: PMC5387170 DOI: 10.1002/cam4.1043
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Study population characteristics at the health examination at baseline, according to cardiorespiratory fitness (CRF) tertiles (n = 1997)
| Characteristics | CRF tertiles [kJ/kg] | ||
|---|---|---|---|
| 1 [<118.9] | 2 [119‐161.4] | 3 [≥161.5] | |
| Age years, mean (SD) | 52.4 (5.2) | 49.9 (5.0) | 46.9 (4.8) |
| <45, | 66 (14.1) | 132 (28.1) | 271 (57.8) |
| 45–49, | 139 (24.5) | 206 (36.3) | 223 (39.2) |
| 50–54, | 218 (39.6) | 209 (38.0) | 123 (22.4) |
| ≥55, | 245 (59.7) | 118 (28.8) | 47 (11.5) |
| CRF kJ/kg, mean (SD) | 91.9 (19.9) | 139.1 (12.3) | 207.9 (50.7) |
| Weight kg, mean (SD) | 76.8 (11.1) | 77.2 (9.5) | 76.5 (9.0) |
| Height cm, mean (SD) | 175.3 (6.1) | 176.8 (5.9) | 178.1 (6.2) |
| BMI kg/m2, mean (SD) | 24.9 (3.1) | 24.7 (2.7) | 24.1 (2.3) |
| <25, | 365 (30.0) | 386 (31.7) | 467 (38.3) |
| ≥25, | 312 (39.6) | 279 (35.4) | 197 (25.0) |
| Smoking ever, | 521 (78.1) | 509 (76.5) | 465 (69.9) |
| Cholesterol mmol/L, mean (SD) | 6.8 (1.2) | 6.7 (1.1) | 6.5 (1.2) |
| Blood pressure, mm/Hg, mean (SD) | |||
| Systolic | 135.3 (19.8) | 129.9 (16.8) | 125.1 (15.0) |
| Diastolic | 89.3 (10.8) | 87.1 (10.0) | 84.9 (9.8) |
SD, standard deviation; BMI, body mass index.
Numbers of the first primary cancers by site diagnosed from baseline (date of health examination) to the end of follow‐up (2012), according to tertiles of cardiorespiratory fitness (CRF)
| Cancer site | ICD‐10 | Total | CRF tertiles | ||
|---|---|---|---|---|---|
| 1 | 2 | 3 | |||
| All sites | C00‐96 | 898 | 278 | 313 | 307 |
| Mouth, pharynx | C00‐14 | 24 | 10 | 8 | 6 |
| Esophagus, stomach | C15, C16 | 43 | 13 | 14 | 16 |
| Colon | C18 | 87 | 35 | 23 | 29 |
| Proximal | C18.0‐18.5 | 46 | 21 | 7 | 18 |
| Distal | C18.6‐18.7 | 41 | 14 | 16 | 11 |
| Rectum, anus | C19‐21 | 44 | 10 | 19 | 15 |
| Liver, gallbladder/bile ducts | C22, C23‐24 | 13 | 4 | 6 | 3 |
| Pancreas | C25 | 29 | 14 | 11 | 4 |
| Lung, trachea | C33‐34 | 109 | 46 | 41 | 22 |
| Prostate | C61 | 213 | 52 | 71 | 90 |
| Kidney, renal pelvis | C64, C65 | 34 | 11 | 12 | 11 |
| Bladder, ureter, urethra | C66‐68 | 76 | 32 | 26 | 18 |
| Skin, melanoma | C43 | 49 | 9 | 15 | 25 |
| Skin, nonmelanoma | C44 | 47 | 12 | 14 | 21 |
| Lymphoma | C81‐90 | 30 | 5 | 13 | 12 |
| Leukemia | C91‐95 | 37 | 9 | 16 | 12 |
| Central nervous system | C70‐72/D42‐43 | 19 | 5 | 6 | 8 |
| Unspecified | C39, C76, C80 | 23 | 8 | 9 | 6 |
| Other sites | 21 | 3 | 9 | 9 | |
Nose (C30‐31), Larynx (C32), Other digestive organs (C26), Other male genitals (C60, C63), Eye (C69), Endocrine glands (C37/C73‐75), Soft tissue (C48‐49).
Hazard ratio (HR) and 95% confidence intervals (CIs) for site‐specific cancer by tertiles of cardiorespiratory fitness (CRF), adjusted for age, body mass index, and smoking at baseline, and P‐values from trend‐tests
| CRF tertiles [kJ/kg, tertile limits, mean per tertile] | Trend | |||
|---|---|---|---|---|
| 1 [<118, 91.9] | 2 [119–161, 139.1] | 3 [>161, 207.9] | ||
| Cancer site | HR | HR (95% CI) | HR (95% CI) |
|
| Mouth/pharynx | 1.00 | 0.64 (0.25,1.65) | 0.41 (0.14,1.19) | 0.25 |
| Esophagus/stomach | 1.00 | 1.09 (0.50,2.36) | 1.24 (0.56,2.77) | 0.86 |
| Colon | 1.00 | 0.60 (0.35,1.01) | 0.69 (0.40,1.17) | 0.15 |
| Proximal | 1.00 | 0.30 (0.13,0.73) | 0.69 (0.34,1.39) | 0.03 |
| Distal | 1.00 | 1.00 (0.48,2.08) | 0.65 (0.28,1.50) | 0.49 |
| Rectum, anus | 1.00 | 1.65 (0.76,3.61) | 1.16 (0.49,2.73) | 0.38 |
| Liver/gallbladder/bile duct | 1.00 | 1.62 (0.44,5.97) | 0.81 (0.16,4.01) | 0.57 |
| Pancreas | 1.00 | 0.80 (0.35,1.80) | 0.32 (0.10,1.00) | 0.15 |
| Lung, trachea | 1.00 | 0.78 (0.50,1.19) | 0.39 (0.23,0.66) | 0.002 |
| Prostate | 1.00 | 1.17 (0.81,1.69) | 1.20 (0.83,1.74) | 0.59 |
| Kidney, renal pelvis | 1.00 | 0.86 (0.37,1.99) | 0.65 (0.27,1.58) | 0.63 |
| Bladder, ureter, urethra | 1.00 | 0.69 (0.41,1.18) | 0.40 (0.21,0.74) | 0.01 |
| Skin cancer | 1.00 | 1.31 (0.73,2.35) | 1.70 (0.96,3.00) | 0.18 |
| Melanoma | 1.00 | 1.48 (0.63,3.42) | 2.19 (0.99,4.96) | 0.14 |
| Nonmelanoma | 1.00 | 1.06 (0.48,2.35) | 1.20 (0.55,2.60) | 0.88 |
| Lymphoma | 1.00 | 2.44 (0.85,6.99) | 1.89 (0.62,5.78) | 0.25 |
| Leukemia | 1.00 | 1.86 (0.80,4.30) | 1.26 (0.49,3.21) | 0.30 |
| Central nervous system | 1.00 | 1.03 (0.31,3.44) | 1.27 (0.38,4.18) | 0.90 |
| Unspecified | 1.00 | 0.97 (0.37,2.58) | 0.59 (0.19,1.82) | 0.59 |
| Other sites | 1.00 | 3.16 (0.83,11.94) | 3.29 (0.81,13.31) | 0.19 |
Nose (C30‐31), Larynx (C32), Other digestive organs (C26), Other male genitals (C60, C63), Eye (C69), Endocrine glands (C37/C73‐75), Soft tissue (C48‐49).